Ownership and insider activity for Regeneron Pharmaceuticals, Inc. (REGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Price
| Price | $726.47 |
| Market Cap | $74.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-02 | McCourt Marion | S-Sale | 1,215 | $1.0M |
| 2026-09-03 | McCourt Marion | S-Sale | 1,131 | $970K |
| 2026-09-02 | Guarini Kathryn | M-Exempt | 400 | $288K |
| 2026-09-02 | Guarini Kathryn | M-Exempt | 400 | $288K |
| 2026-09-02 | Guarini Kathryn | S-Sale | 400 | $340K |
| 2026-08-19 | LAROSA JOSEPH J | M-Exempt | 12,282 | $4.7M |
| 2026-08-19 | LAROSA JOSEPH J | F-InKind | 9,019 | $7.5M |
| 2026-08-19 | LAROSA JOSEPH J | M-Exempt | 12,282 | $4.7M |
| 2026-08-18 | Fenimore Christopher R. | M-Exempt | 6,283 | $2.4M |
| 2026-08-18 | Fenimore Christopher R. | F-InKind | 4,599 | $3.7M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $535.2M | $812.7M | $1.47B | $1.62B | $2.19B | $2.89B | $3.11B | $2.73B | $2.49B | $3.12B |
| Short-term Investments | $503.5M | $596.8M | $1.34B | $1.60B | $1.39B | $2.81B | $4.64B | $8.11B | $6.52B | $5.49B |
| Receivables | $1.61B | $1.97B | $2.24B | $2.79B | $4.11B | $6.04B | $5.33B | $5.67B | $6.21B | $5.74B |
| Inventory | $399.4M | $726.1M | $1.15B | $1.42B | $1.92B | $1.95B | $2.40B | $2.58B | $3.09B | $3.20B |
| Total Current Assets | $3.91B | $5.60B | $7.96B | $7.69B | $9.78B | $14.01B | $15.88B | $19.48B | $18.66B | $18.02B |
| Property, Plant & Equipment | $2.08B | $2.36B | $2.58B | $2.89B | $3.22B | $3.48B | $3.76B | $4.15B | $4.60B | $5.12B |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $6.7M | $915.5M | $1.04B | $1.15B | $1.26B |
| Total Assets | $6.97B | $8.76B | $11.73B | $14.81B | $17.16B | $25.43B | $29.21B | $33.08B | $37.76B | $40.56B |
| Accounts Payable | $135.0M | $178.2M | $218.2M | $418.1M | $475.5M | $564.0M | $589.2M | $606.6M | $789.5M | $939.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.24B | $1.14B | $1.44B | $2.10B | $2.70B | $3.93B | $3.14B | $3.42B | $3.94B | $4.37B |
| Long-term Debt | 0 | 0 | 0 | 0 | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B |
| Total Liabilities | $2.52B | $2.62B | $2.98B | $3.72B | $6.14B | $6.67B | $6.55B | $7.11B | $8.41B | $9.30B |
| Retained Earnings | $1.75B | $2.95B | $5.25B | $7.38B | $10.89B | $18.97B | $23.31B | $27.26B | $31.67B | $35.80B |
| Total Equity | $4.45B | $6.14B | $8.76B | $11.09B | $11.03B | $18.77B | $22.66B | $25.97B | $29.35B | $31.26B |
| Total Debt | $481.1M | $703.5M | $708.5M | $713.9M | $2.70B | $2.70B | $2.70B | $2.70B | $2.70B | $2.71B |
| Net Debt | -$557.6M | -$706.0M | -$2.10B | -$2.50B | -$891.3M | -$3.00B | -$5.04B | -$8.14B | -$6.31B | -$5.90B |
| Working Capital | $2.67B | $4.46B | $6.52B | $5.59B | $7.08B | $10.08B | $12.74B | $16.06B | $14.72B | $13.65B |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 3.34 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 7.49 |
Profitability
| Return on Equity | 14.41% |
| Return on Invested Capital | 8.51% |
| Return on Assets | 11.11% |
| Gross Margin | 84.86% |
| Operating Margin | 25.56% |
| Net Margin | 27.86% |
Related companies: ALNY · ARGX · CI · COR · ELV · GMAB · IDXX
Explore sector: Healthcare · Biotechnology
More sections of REGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks